Consensus Virbac

Stocks

Real-time Euronext Paris 22:21:39 03/11/2026 HKT			5-day change	1st Jan Change
354.00 ^EUR	0.00%		+1.58%	-0.98%

10-20	Virbac: A well-done Q3 validates underlying quality
10-20	Virbac stock little changed despite strong update and targets now expected at the top end of the range

61f5d43011929.DA6xNO12MyaoxMh-QpbjyoW-HASu6KdltmwyUGZZ5sQ.YWjJZogVAUTsjrgECuGUs-vLRmnNhfcy5iVCAyEdoqpCaoZ1py5KXsyl-A~9be05e46bf6bbfaa4fb6cd4ebc983c85

10-20	Virbac: A well-done Q3 validates underlying quality
10-20	Virbac stock little changed despite strong update and targets now expected at the top end of the range
08-20	Cancer vaccines finally garner the spotlight
07-22	Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3
07-14	Where would AI lead Pharma in the long run?
05-11	Virbac continues decline despite positive recommendation
04-17	Virbac: 2026 starts on strong footing
03-19	Stifel sees Virbac as undervalued, sets 440 euro price target
03-18	Virbac in the green following results and outlook
01-20	Virbac beats 2025 targets, lifts 2026 outlook
01-20	Stifel Raises Price Target on Virbac
01-20	Virbac Significantly Outperforms the Market with Annual Revenues and 2026 Targets
17/10/25	Virbac: Q3 crushed doubts about execution ability
17/09/25	The day the Fed resumed its rate cuts
15/09/25	Virbac: Oddo BHF remains positive despite H1 results
17/07/25	Virbac: A healthy Q2 impresses the markets
03/07/25	Oddo BHF Upgrades Virbac to Outperform, Boosts PT	MT
03/07/25	Virbac: Oddo BHF upgrades stock
17/04/25	Virbac: brokers' advice following quarterly results
16/04/25	Virbac: Stifel remains bullish after quarterly results
16/04/25	Virbac: Decent Q1; Clarity on US tariff exposure was a key takeaway
16/04/25	Virbac: Stifel still buying after Q1 results
17/03/25	Virbac: Oddo BHF remains 'neutral', confirms its target
17/03/25	Virbac: 2024 profitability somewhat exceeded expectations; stock re-rating underway
17/03/25	Virbac: Stifel raises its recommendation

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VIRBAC					+16.46%
	ELI LILLY AND COMPANY					+1.13%
	JOHNSON & JOHNSON					+3.27%
	ABBVIE INC.					+5.79%
	ROCHE HOLDING AG					-0.68%
	MERCK & CO., INC.					+7.78%
	NOVARTIS AG					-4.27%
	ASTRAZENECA PLC					+14.77%
	AMGEN INC.					-14.64%
	GILEAD SCIENCES, INC.					+1.27%
	Average					+3.09%
	Weighted average by Cap.					+2.06%